Chapter 9: Antibody Based Radiopharmaceuticals in Clinical Development Check Access

This chapter explores the utility and future prospects of antibody-based radiopharmaceuticals in clinical development. Different types of monoclonal antibodies have been used for diagnosis and treatment of various cancers by harnessing their inherent biological functions. Continuous advancements in processes, such as their production and fragmentation, have led to the development of newer and more effective targeting antibody molecules. Several tumor antigen targets, like epidermal growth factor receptor, carcinoembryonic antigen, programmed cell death protein 1, programmed cell death ligand 1, cluster of differentiation (CD) 5, CD 20, and CD 45 have been explored for development of radiopharmaceuticals for different tumor types. The high specificity and affinity to antigen targets, in addition to the emissions from radioisotopes, make radiolabeled monoclonal antibodies ideal agents for propagation of personalized medicine approaches. The aim of this chapter is to provide a comprehensive overview of the applications of radiolabeled monoclonal antibodies in oncological settings from bench to bedside.